Argus Research Maintains Buy on Cencora, Raises Price Target to $380
10/20/2026
Impact: 85
Healthcare
Argus Research analyst David Toung has maintained a 'Buy' rating on Cencora (NYSE: COR) and increased the price target from $340 to $380. This adjustment reflects a positive outlook on the company's performance.
AI summary, not financial advice
Share: